P/E của cổ phiếu LCTX là bao nhiêu?

Lineage Cell Therapeutics Inc (LCTX) hiện giao dịch ở mức P/E 325.17 lần.

ROE của cổ phiếu LCTX là bao nhiêu?

Lineage Cell Therapeutics Inc có tỷ suất lợi nhuận trên vốn chủ sở hữu (ROE) -119.18%.

Tỷ suất cổ tức của LCTX là bao nhiêu?

Lineage Cell Therapeutics Inc có tỷ suất cổ tức 0.00%.

Điểm chất lượng (Quality Score) của LCTX là bao nhiêu?

AI của chúng tôi đánh giá chất lượng tài chính tổng thể của LCTX ở mức 46/100, dựa trên khả năng sinh lời, tăng trưởng, nợ và độ ổn định lợi nhuận.

Bây giờ có nên mua cổ phiếu LCTX không?

Điểm AI Timing của LCTX là 28/100, thể hiện mức độ hấp dẫn tương đối của giá hiện tại theo tín hiệu kỹ thuật và momentum — nên cân nhắc cùng điểm chất lượng và kế hoạch đầu tư của bạn.

Cổ phiếu LCTX thuộc ngành nào?

Lineage Cell Therapeutics Inc được xếp vào ngành Healthcare >> Biotechnology trên sàn NYSE MKT

Cổ phiếu LCTX (NYSE MKT) | LINEAGE CELL THERAPEUTICS INC

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-04 | FS: 2026-03-31)

LCTX AI Analysis Summary

Our AI summary for LCTX: Lineage Cell Therapeutics Inc (NYSE MKT), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 325.17, ROE of -119.18%, a dividend yield of 0.00%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 28/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

LCTX

Lineage Cell Therapeutics Inc

US:NYSE MKT STOCK Healthcare >> Biotechnology News 99

USD 1.12

0.01 (0.90%) Day Change

Watchlist Portfolio Compare Chart

325.17

P/E

0.02

D/E

-119.2%

ROE

-58.6%

ROA

0.00%

Div Yield

LINEAGE CELL THERAPEUTICS INC
TYPE: STOCK
MARKET: NYSE MKT

Compare Watchlist Myport

USD 1.12 Price 0.01 (0.90%) Day Change	NEWS SCORE: 99

LCTX Chất lượng tổng thể của cố phiếu Không tốt ( Chất lượng = 46) và Thời điểm mua ...(Sign In to See)...

Loading chart...

46 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: Tỷ lệ P/E tương đối cao
Tỷ lệ ROE tương đối thấp
Tỷ lệ ROA tương đối thấp
Lịch sử ROE tương đối thấp
Tăng trưởng ROE là âm trong năm ngoái.
Tăng trưởng ROA dưới mức tiêu chí của chúng tôi trong năm vừa qua
Biên lợi nhuận ròng tương đối thấp.
Lịch sử Biên lợi nhuận ròng tương đối thấp.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Khá , ...

Yếu tố Chất lượng

44%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	99
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	1.12
PBV / Sector	5.25 / 44,022.72
Earning Per Share	-0.26

PE / Sector	325.17 / 19.17
PEG or PE/Growth / Sector	N/A / 1.24
Average 1M Daily Value	1.11 M GREAT
Average 1W Daily Value	1.00 M GREAT

Yếu tố Kỹ thuật

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Sức khỏe tài chính

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Khả năng kiếm lợi nhuận

62%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-434.44 / 98.24
NPM Average (%) / Sector	-297.14 / -1,697.63
NPM Change Average (%) / Sector	34.58 / 5,097.97 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-58.62 / 185,260.96
ROA Average (%) / Sector	-34.80 / 36,684.70
ROA Change Average (%) / Sector	56.15 / 422,221.66 GREAT
ROE (%) / Sector	-119.18 / 243,762.23
ROE Average (%) / Sector	-71.05 / 48,758.47
ROE Change Average (%) / Sector	112.23 / 424,968.10 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Lợi tức cho nhà đầu tư

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.49

Chi tiết đăng ký

Analyze Date	2026-08-05 08:00:28
Symbol	LCTX
Name	LINEAGE CELL THERAPEUTICS INC
Sector	Healthcare >> Biotechnology
Market	NYSE MKT
Listed Shares	249.30 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	276.72 / 9,586.08

Tin tức, Dự báo ước tính

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 2173 Salk Avenue, Carlsbad, CA, United States, 92008

Phone: 442 287 8990

Website: https://www.lineagecell.com

Employees: 72

Sector: Healthcare >> Biotechnology

Description: Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.